Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Olaparib, a PARP inhibitor, is a standard maintenance therapy for ovarian cancer.
• Dose modifications (reduction, interruption) are common to manage olaparib's adverse events (AEs).
• Identifying patients at high risk for dose modification can guide proactive AE management.

Purpose of the Study:

• To evaluate risk factors for olaparib dose modification in ovarian cancer patients.
• To assess the clinical utility of identified risk factors for predicting treatment outcomes.

Main Methods:

• Retrospective cohort study of 60 ovarian cancer patients treated with olaparib.
• Multivariate logistic regression analysis to identify associations between patient characteristics and dose modification.
• Receiver operating characteristic (ROC) curve analysis to determine optimal age cutoff for risk stratification.

Main Results:

• 41.7% of patients required olaparib dose modification.
• Older age (p=0.018) and tendency towards underweight (p=0.078) were associated with dose modification.
• Increasing age was a significant independent risk factor for dose modification (OR=1.056, p=0.034).
• Optimal age cutoff for dose modification risk was 65.0 years.
• Patients aged ≥65.0 years were significantly more likely to discontinue olaparib due to AEs (p=0.0437).

Conclusions:

• Increasing age is a significant risk factor for olaparib dose modification in ovarian cancer.
• Older patients requiring dose modification face a higher likelihood of treatment discontinuation due to AEs.
• Strict AE management is crucial for elderly patients receiving olaparib maintenance therapy.